3M Company
164.63-2.20 (-1.32%)
Oct 29, 4:00:02 PM EDT · NYSE · MMM · USD
Report date
≈ Jan 20, 2026 (in 82 days)EPS
1.99 (1.94 ~ 2.04)Revenue
6.05B (5.91B ~ 6.25B)Key Stats
Market Cap
87.46BP/E (TTM)
26.26Basic EPS (TTM)
6.27Dividend Yield
0.02%Recent Filings
10-Q
Q3 FY2025 results
3M's Q3 sales climbed 3.5% year-over-year to $6.5 billion, with organic growth of 2.6% fueled by strength in safety gear and electronics, though automotive aftermarket lagged. Operating income rose 10% to $1.4 billion, lifting margins to 22.2% from 20.9%, thanks to productivity gains and lower restructuring costs, yet tempered by a $161 million divestiture charge and litigation hits. Diluted EPS from continuing operations fell 38% to $1.55, pressured by Solventum stake valuation swings, but adjusted figures show 10% growth to $2.19. Cash dipped to $4.7 billion after $3.2 billion in PFAS and earplug settlements, while net debt edged up to $7.4 billion amid $1.8 billion maturities offset by issuances. Free cash flow turned positive at $61 million, derived from $723 million operating cash minus $662 million capex. Ongoing PFAS regulatory scrutiny poses persistent risks.
8-K
3M boosts Q3 results, guidance
3M reported Q3 2025 GAAP sales of $6.5 billion, up 3.5% year-over-year, with adjusted organic growth hitting 3.2%. Adjusted operating margin climbed to 24.7%, boosting adjusted EPS 10% to $2.19, while operating cash flow reached $1.8 billion. The company raised full-year adjusted EPS guidance to $7.95-$8.05, signaling stronger margins ahead. Yet litigation costs linger as a key risk.
8-K
Board member retires
8-K
3M boosts EPS guidance
3M reported Q2 2025 GAAP sales of $6.3 billion, up 1.4% year-over-year, but EPS fell 38% to $1.34 amid heavy litigation costs; adjusted figures shone brighter, with sales up 2.3% and EPS climbing 12% to $2.16, while operating margin expanded 2.9 points to 24.5%. All three business groups posted organic growth for the third straight quarter, fueling confidence in the 3M eXcellence model. Tariffs now baked into outlook. Adjusted EPS guidance lifted to $7.75-$8.00, yet litigation drags persist.
10-Q
Q2 FY2025 results
3M's Q2 sales edged up 1.4% to $6.3B, with organic growth of 0.6% driven by electronics and industrial adhesives, though automotive OEM softened. Operating income dipped to $1.1B from $1.3B, pressured by a $281M charge for the New Jersey PFAS settlement, yet margins held at 18.0% amid productivity gains and lower restructuring costs. Diluted EPS from continuing operations fell 38% to $1.34, reflecting litigation hits and a prior-year pension settlement, but adjusted EPS climbed 12% to $2.16 on share repurchases and gains from an investment sale. Cash dropped to $3.7B after $3.1B in PFAS and earplug settlement payments, while net debt rose to $8.9B; free cash flow turned negative at -$1.5B (derived). The fused silica divestiture closed in June for immaterial proceeds. Ongoing PFAS regulatory scrutiny poses persistent risks.
AVY
Avery Dennison Corporation
176.20-2.97
EMR
Emerson Electric Company
136.43+1.91
FUJIF
FUJIFILM Holdings Corp.
24.10+0.00
HON
Honeywell International Inc.
212.89-1.52
MATW
Matthews International Corporat
23.16-0.15
MICLF
Mycronic AB
18.10+0.00
MSFT
Microsoft Corporation
541.55-0.52
NNBR
NN, Inc.
1.90+0.02
PG
Procter & Gamble Company (The)
148.77-2.60
RCMT
RCM Technologies, Inc.
22.65+0.03